Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Resistance of gram negative bacilli to various antimicrobials

From: Emerging antimicrobial resistance in early and late-onset neonatal sepsis

Organism (number) Ampicillin-sulbactam Amikacin Cefotaxime Ceftazidime Imipenem Vancomycin Ciprofloxacin Clindamycin   Rifampicin Piperacillin-tazobactam
Kl(105) 105(100%) 45(43%) 103(98.1%) 105(100%) 22(21%) ND 48(45.7%) ND   ND 103(98.1%)
Pseudomonas (44) 44(100%) 12(27.3%) 39(88.6%) 41(93.2%) 17(38.6%) ND 22(50%) ND   ND 44(100%)
Acinetobacter (24) 24(100%) 8(33.3%) 20(83.3%) 21(87.5%) 9(37.5%) ND 8(33.3%) ND   ND 24(100%)
Salmonella (1) 1(100%) 1(100%) 1(100%) 1(100%) 0 ND 0 ND   ND 1(100%)
E coli (6) 6(100%) 1(16.7%) 4(66.7%) 5(83.3%) 0 ND 2(33.3%) ND   ND 6(100%)
Enterobacter (12) 12(100%) 3(25%) 12(100%) 12(100%) 2(16.7%) ND 5(41.7%) ND   ND 12(100%)
Stenotrophomonas(2) 2(100%) 0 2(100%) 2(100%) 1(50%) ND 2(100%) ND   ND 2(100%)
  Gentamicin Meropenem Cefoperazone Cefepime Amoxicillin-clavulanate Ceftriaxone Cotrimoxazole Erythromycin Cefoxitin Levofloxacin Cefuroxime
Kl (105) 63(60%) 34(32.4%) 103(98.1%) 86(81.9%) 101(96.2%) 103(98.1%) 86(81.9%) ND 82(78.1%) 25(24%) 105(100%)
Pseudomonas (44) 21(47.7%) 20(45.5%) 39(88.6%) 28(63.6%) 43(97.7%) 44(100%) 37(84.1%) ND 38(86.4%) 8(18%) 44(100%)
Acinetobacter (24) 7(29.2%) 10(41.7%) 21(87.5%) 14(58.3%) 24(100%) 24(100%) 19(79.2%) ND 16(66.7%) 7(29%) 24(100%)
Salmonella (1) 1(100%) 0 1(100%) 1(100%) 1(100%) 1(100%) 0 ND 1(100%) 0 1(100%)
E coli (6) 1(16.7%) 0 6(100%) 5(83.3%) 6(100%) 6(100%) 2(33.3%) ND 2(33.3%) 1(17%) 6(100%)
Enterobacter(12) 8(66.7%) 4(33.3%) 12(100%) 8(66.7%) 11(91.7%) 12(100%) 10(83.3%) ND 11(91.7%) 3(25%) 12(100%)
Stenotrophomonas(2) 0 1(50%) 2(100%) 2(100%) 2(100%) 2(100%) 2(100%) ND 1(50%) 2(100%) 2(100%)
  1. ND Sensitivity was not done, E coli Escherichia coli, Klebsiella Klebsiella pneumoniae, Pseudomonas Pseudomonaas aeruginosa